Prostate International最新文献

{"title":"The impact of obesity and sexual behavior on prostate cancer risk is mediated by testosterone levels: a mendelian randomization study and mediation analysis","authors":"Huajie Di ,&nbsp;Yi Wen ,&nbsp;Junyan Wang ,&nbsp;Jiayu Wang ,&nbsp;Yeqing Wang ,&nbsp;Yuan Li ,&nbsp;Fanghao Sun","doi":"10.1016/j.prnil.2024.03.003","DOIUrl":"10.1016/j.prnil.2024.03.003","url":null,"abstract":"<div><h3>Background</h3><p>The relationship between obesity, sexual behavior, and prostate cancer (PCa) has been widely debated, contributing to a lack of understanding of its potential mechanisms and hindering the development of effective prevention measures.</p></div><div><h3>Purpose</h3><p>The aim of this study was to examine the causal effect of body mass index (BMI), age at first sexual intercourse (AFS), and bioavailable testosterone levels on PCa while also quantifying the potential roles of mediators.</p></div><div><h3>Method</h3><p>We conducted a Mendelian randomization (MR) study using summary statistics from genome-wide associations of BMI (152,893 European males), AFS (182,791 European males), bioavailable testosterone (184,205 European males), and PCa (79,148 cases, 61,106 controls, European ancestry). Inverse-variance weighted method, weighted median method, MR-Egger regression, Least Absolute Shrinkage and Selection Operator (LASSO), and outlier test were used for MR analyses. Reverse MR and mediation analysis were performed. Data analyses were conducted from December 2022 to July 2023.</p></div><div><h3>Results</h3><p>The results showed that genetic liability to BMI was protective of PCa (OR, 0.82; 95% CI: 0.74-0.91; <em>P</em> = 3.29 × 10⁻⁴). Genetic liability to later AFS (OR, 1.28; 95% CI: 1.08-1.53; <em>P</em> = 5.64 × 10⁻³) and higher bioavailable testosterone levels (OR = 1.11, 95% CI: 1.01–1.24, <em>P</em> = 0.04) were associated with an increased risk of PCa. All of these potential causal effects could only be forwarded and were not affected by prostate specific antigen (PSA) screening. After controlling for bioavailable testosterone levels, the causal impact of BMI and AFS on PCa was no longer significant. The mediation analysis suggested that the causal influence of AFS/BMI on PCa relied on bioavailable testosterone levels.</p></div><div><h3>Conclusion</h3><p>In conclusion, the difference between the univariable and multivariable MR results suggested that the causal influence of BMI and AFS on PCa relied on bioavailable testosterone levels. Further work is needed to identify other risk factors and to elucidate the specific mechanisms that underlie this causal pathway.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 2","pages":"Pages 96-103"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888224000230/pdfft?md5=ff5b57541bc01564214d012434eb8ab7&pid=1-s2.0-S2287888224000230-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140399036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Propensity score matched analysis of functional outcome in five thousand cases of robot-assisted radical prostatectomy versus high-intensity focused ultrasound","authors":"Junhyun Nam ,&nbsp;Jung Kwon Kim ,&nbsp;Jong Jin Oh ,&nbsp;Sangchul Lee ,&nbsp;Seok-Soo Byun ,&nbsp;Sung Kyu Hong ,&nbsp;Sang Hun Song","doi":"10.1016/j.prnil.2024.03.004","DOIUrl":"10.1016/j.prnil.2024.03.004","url":null,"abstract":"<div><h3>Background</h3><p>To evaluate functional outcome after robot-assisted radical prostatectomy (RARP) and high-intensity focused ultrasound (HIFU) ablation for prostate cancer.</p></div><div><h3>Methods</h3><p>We retrospectively reviewed 4,983 RARP and 230 HIFU procedures performed at a single tertiary center. A 1:4 ratio propensity score matching (PSM) was performed to achieve baseline equivalence in age, body mass index (BMI), comorbidities, clinical stage, prostate specific antigen (PSA), prostate volume, biopsy grade, and number of positive cores. Functional outcomes based on International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-5) scores, and incontinence rates were evaluated at 6, 12, and 24 months.</p></div><div><h3>Results</h3><p>total of 193 HIFU cases matched to 760 cases of RARP, were included. No differences were observed in perioperative IPSS at all follow-up periods. Despite comparative erectile function at baseline, HIFU showed significantly better erectile function preservation compared to RARP, with mean IIEF-5 scores of 9.5 versus 4.8, 9.5 versus 5.8, and 8.4 versus 6.7 at 6, 12, and 24 months, respectively (all <em>P</em> &lt; 0.001). Pad-free rates at 6 and 12 months were comparable, with over 96% achieving continence at 12 months in both groups, although the rate of ≤1 pad/day at last follow-up was slightly better in HIFU (98.9% vs. 96.7%, <em>P</em> = 0.049). Subgroup analysis on partial (PGA) and whole gland ablation (WGA) showed no differences in IIEF-5 and incontinence but increased voiding difficulty in WGA versus PGA after 12 months of therapy (<em>P</em> &lt; 0.05). Preoperative IIEF-5 ≥17 and HIFU were significant predictors of early erectile function recovery at 6 months (HR 4.4 and 5.0; all <em>P</em> &lt; 0.001). No differences were observed in treatment-free survival between PGA, WGA, and RARP.</p></div><div><h3>Conclusion</h3><p>HIFU shows better performance in early recovery and preservation of erectile function after treatment for prostate cancer without increasing the risk of treatment failure. Patients with moderate to severe erectile dysfunction (IIEF-5 &lt;17) prior to surgery should be warned of poor recovery after treatment.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 2","pages":"Pages 104-109"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888224000242/pdfft?md5=f1637b0c9f5fa45b613b5aec5c2d86ba&pid=1-s2.0-S2287888224000242-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140407001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy","authors":"Isaac E. Kim Jr. ,&nbsp;Aaron H. Wang ,&nbsp;George S. Corpuz ,&nbsp;Preston C. Sprenkle ,&nbsp;Michael S. Leapman ,&nbsp;Joseph M. Brito ,&nbsp;Joseph Renzulli ,&nbsp;Isaac Yi Kim","doi":"10.1016/j.prnil.2024.01.002","DOIUrl":"10.1016/j.prnil.2024.01.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Although the clinical benefits of pelvic lymph node dissection (PLND) at the time of radical prostatectomy for prostate cancer remain uncertain, major guidelines recommend PLND based on risk profile. Thus, the objective of this study was to examine the association between PLND and survival among patients undergoing RP stratified by Gleason grade group (GG) with the aim of allowing patients and physicians to make more informed care decisions about the potential risks and benefits of PLND.</p></div><div><h3>Materials and methods</h3><p>From the SEER-17 database, we examined overall (OS) and prostate cancer-specific (PCSS) survival of prostate cancer patients who underwent RP from 2010 to 2015 stratified by GG. We applied propensity score matching to balance pre-operative characteristics including race, age, PSA, household income, and housing status (urban/rural) between patients who did and did not undergo PLND for each GG. Statistical analyses included log-rank test and Kaplan-Meier curves.</p></div><div><h3>Results</h3><p>We extracted a matched cohort from 80,287 patients with GG1-5 who underwent RP. The median PSA value was 6.0 ng/mL, and the median age was 62-years-old. 49,453 patients underwent PLND (61.60%), while 30,834 (38.40%) did not. There was no difference in OS and PCSS between patients who received PLND and those who did not for all Gleason GG (OS–GG1: <em>P</em> = 0.20, GG2: <em>P</em> = 0.34, GG3: <em>P</em> &gt; 0.05, GG4: <em>P</em> = 0.55, GG5: <em>P</em> = 0.47; PCSS–GG1: <em>P</em> = 0.11, GG2: <em>P</em> = 0.96, GG3: <em>P</em> = 0.81, GG4: <em>P</em> = 0.22, GG5: <em>P</em> = 0.14).</p></div><div><h3>Conclusions</h3><p>In this observational study, PLND at the time of RP was not associated with improved OS or PCSS among patients with cGS of 3 + 3, 3 + 4, 4 + 3, 4 + 4, 4 + 5, and 5 + 4. These findings suggest that until definitive clinical trials are completed, prostate cancer patients who have elected RP should be appropriately counseled on the potential risks and lack of proven survival benefit of PLND.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 2","pages":"Pages 70-78"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888224000023/pdfft?md5=0ca840c0e08106ea2975754f1f3bfaba&pid=1-s2.0-S2287888224000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139828666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between depression, anxiety and lower urinary tract symptoms in men","authors":"Yu Seob Shin ,&nbsp;Kiran Kumar Soni ,&nbsp;Dong Yun Lee ,&nbsp;Sung Chul Kam","doi":"10.1016/j.prnil.2024.02.002","DOIUrl":"10.1016/j.prnil.2024.02.002","url":null,"abstract":"<div><h3>Purpose</h3><p>Patients with lower urinary tract symptoms (LUTS) often experience comorbid depression and anxiety, yet the mechanisms underlying this association remain incompletely understood. This prospective study aimed to investigate the relationship between depression, anxiety, and LUTS in men.</p></div><div><h3>Materials and methods</h3><p>A prospective study was conducted with 350 male patients who underwent urologic examinations at our institution from January 2021 to December 2021. Of these, 131 patients meeting the inclusion criteria were included. Various questionnaires, including the International Prostate Symptom Score (IPSS) and the Hospital Anxiety and Depression Scale (HADS), as well as LUTS examinations (prostate-specific antigen test, transrectal ultrasonography, and urine flowmetry), were administered.</p></div><div><h3>Results</h3><p>Among the 350 patients, 131 were included in the analysis, with an average age of 58.0 ± 13.69 years. The total IPSS was 18.0 ± 8.69, with the average voiding symptom score at 8.7 ± 5.19 and the average storage symptom score at 6.0 ± 3.27. Both anxiety and depression were found to be correlated with LUTS (<em>P</em> &lt; 0.05). After adjusting for age, hypertension, and diabetes, anxiety (but not depression) was significantly associated with LUTS based on regression analysis.</p></div><div><h3>Conclusion</h3><p>Men with LUTS are more likely to experience anxiety. Therefore, it is essential to assess and address anxiety when managing men with LUTS.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 2","pages":"Pages 86-89"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888224000047/pdfft?md5=b0ad1e4c42a40a8a646787b57382c304&pid=1-s2.0-S2287888224000047-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140005439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risks and side effects in the medical management of benign prostatic hyperplasia","authors":"Abdulghafour Halawani ,&nbsp;Ryan Paterson ,&nbsp;Tianshuang Zhong ,&nbsp;Katie Du ,&nbsp;Runhan Ren ,&nbsp;Connor M. Forbes","doi":"10.1016/j.prnil.2023.11.004","DOIUrl":"10.1016/j.prnil.2023.11.004","url":null,"abstract":"<div><p>Benign prostatic hyperplasia affects up to 80% of men in their lifetime. It causes bladder outflow obstruction, leading to lower urinary tract symptoms, which can have a large impact on quality of life. Lifestyle modifications and pharmacotherapy are often offered as first-line treatments for patients. These include alpha blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors, anticholinergics, B3-agonists, and desmopressin. While often well tolerated, these pharmacotherapies do have significant side effects, which both clinicians and patients should understand and discuss in order to make an informed treatment decision among alternatives. The purpose of this review is to provide a current overview of the risks and side effects of commonly used medications in benign prostatic hyperplasia management.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 2","pages":"Pages 57-64"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888223000612/pdfft?md5=c109359cfa332b99fd9e90dc0c24fee7&pid=1-s2.0-S2287888223000612-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138519701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does androgenic alopecia aggravate the risk of prostate cancer? Evidence from Mendelian randomization","authors":"Xianghua Shi ,&nbsp;Yuan Pan ,&nbsp;Jianhua Liu ,&nbsp;Fei Luo ,&nbsp;Binbin Li ,&nbsp;Yuan Hu ,&nbsp;Kai Chen","doi":"10.1016/j.prnil.2024.04.001","DOIUrl":"10.1016/j.prnil.2024.04.001","url":null,"abstract":"<div><h3>Background</h3><p>Epidemiological reports indicate a potential association between androgenic alopecia (AGA) and increased prostate cancer (PC) prevalence, but conflicting reports also exist. This study aims to elucidate the causality of AGA on PC risk using Mendelian randomization (MR) analysis.</p></div><div><h3>Materials and methods</h3><p>Two-sample MR analyses utilized public genome-wide association studies summary data for single-nucleotide polymorphisms associated with AGA. Four statistical methods were used: inverse variance weighted (IVW), MR-Egger, weighted median, and weighted mode, with IVW as the preliminary estimation method. Additionally, sensitivity analyses were conducted to address pleiotropic bias.</p></div><div><h3>Results</h3><p>Genetically proxied AGA did not demonstrate a causal effect on PC risk (IVW <em>P</em> &gt; 0.05). Consistently, complementary methods yielded results aligned with IVW.</p></div><div><h3>Conclusions</h3><p>Our MR analysis indicates no causal relationship between genetically predicted AGA and PC risk, suggesting that observed associations in epidemiological studies may not be causal.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 2","pages":"Pages 110-115"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888224000266/pdfft?md5=4a15fc861ca5748549ec52b1499355f2&pid=1-s2.0-S2287888224000266-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140769253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical management of post prostatectomy incontinence","authors":"Natalija Kovacevic ,&nbsp;Priya Padmanabhan","doi":"10.1016/j.prnil.2024.04.005","DOIUrl":"10.1016/j.prnil.2024.04.005","url":null,"abstract":"<div><p>Post prostatectomy incontinence (PPI) is a well-recognized and bothersome complication following radical prostatectomy. Conservative measures such as pelvic floor physical therapy, biofeedback, and medication are first line management of PPI. When first line therapies fail, patients are offered a variety of surgical procedures based on the degree of incontinence, prior radiation therapy, and comorbidities. Among the various surgical options, placement of an artificial urinary sphincter (AUS) is the gold standard for PPI. However, AUS placement has a high rate of re-operation and requires good manual dexterity. In cases of mild-moderate incontinence, especially in patients without prior radiation therapy, male slings and proACT are a less invasive option. Bulking therapy, although highly successful for female stress urinary incontinence (SUI), is not currently advised in the treatment of male SUI. Regardless of surgical approach used to treat PPI, providers should counsel patients regarding risks of re-operation and have an open an honest discussion regarding the degree of continence that can be restored following each procedure.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 2","pages":"Pages 65-69"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888224000308/pdfft?md5=a99f484226677a2ba056a56c679aba13&pid=1-s2.0-S2287888224000308-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141063315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the potential of ex-vivo 7-T magnetic resonance imaging on patients with clinically significant prostate cancer: visibility and size perspective","authors":"Hyungwoo Ahn ,&nbsp;Jung Kwon Kim ,&nbsp;Sung Il Hwang ,&nbsp;Sung Kyu Hong ,&nbsp;Seok-Soo Byun ,&nbsp;Sang Hun Song ,&nbsp;Gheeyoung Choe ,&nbsp;Hye Mi Jee ,&nbsp;Sung Woo Park","doi":"10.1016/j.prnil.2024.02.001","DOIUrl":"10.1016/j.prnil.2024.02.001","url":null,"abstract":"<div><h3>Background</h3><p>Despite progress in multiparametric magnetic resonance imaging (MRI), issues of prostate cancer invisibility and underestimated tumor burden persist. This study investigates the potential of an ultra-high field MRI at 7-T in an <em>ex-vivo</em> setting to address these limitations.</p></div><div><h3>Methods</h3><p>This prospective study included 54 tumors from 20 treatment-naïve clinically significant prostate cancer patients, confirmed by biopsy, despite negative findings on preoperative 3-T MRI. <em>Ex-vivo</em> 7-T MRI of resected prostates was performed, with assessment on tumor visibility and size. Factors influencing visibility were analyzed using logistic regression analyses.</p></div><div><h3>Results</h3><p>Tumor visibility was confirmed in 80% of patients, and 48% of all tumors on <em>ex-vivo</em> imaging. Gleason pattern 4 percentage (odds ratio 1.09) and tumor size on pathology (odds ratio 1.36) were significantly associated with visibility (<em>P</em> &lt; 0.05). Mean MRI-visible and invisible tumor sizes were 10.5 mm and 5.3 mm, respectively. The size discrepancy between MRI and pathology was 2.7 mm.</p></div><div><h3>Conclusion</h3><p>Tumor visibility on <em>ex-vivo</em> 7-T MRI was influenced by tumor grade and size. The notable tumor visibility initially overlooked on 3-T MRI, along with small size discrepancy with pathology, suggests potential improvements in resolution.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 2","pages":"Pages 79-85"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888224000035/pdfft?md5=2c4731d30af6ea08beaf886d312b2a36&pid=1-s2.0-S2287888224000035-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139951976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate cancer nomograms and their application in Asian men: a review","authors":"Sridhar Panaiyadiyan,&nbsp;Rajeev Kumar","doi":"10.1016/j.prnil.2023.07.004","DOIUrl":"10.1016/j.prnil.2023.07.004","url":null,"abstract":"<div><p>Nomograms help to predict outcomes in individual patients rather than whole populations and are an important part of evaluation and treatment decision making. Various nomograms have been developed in malignancies to predict and prognosticate clinical outcomes such as severity of disease, overall survival, and recurrence-free survival. In prostate cancer, nomograms were developed for determining need for biopsy, disease course, need for adjuvant therapy, and outcomes. Most of these predictive nomograms were based on Caucasian populations. Prostate cancer is significantly affected by race, and Asian men have a significantly different racial and genetic susceptibility compared to Caucasians, raising the concern in generalizability of these nomograms. We reviewed the existing literature for nomograms in prostate cancer and their application in Asian men. There are very few studies that have evaluated the applicability and validity of the existing nomograms in these men. Most have found significant differences in the performance in this population. Thus, more studies evaluating the existing nomograms in Asian men or suggesting modifications for this population are required.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 1","pages":"Pages 1-9"},"PeriodicalIF":3.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888223000375/pdfft?md5=02a4aeda1182a32fdf578fb64dd725b5&pid=1-s2.0-S2287888223000375-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48246419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-power holmium laser versus thulium fiber laser for endoscopic enucleation of the prostate in patients with glands larger than 80 ml: Results from the Prostate Endoscopic EnucLeation study group","authors":"Ee Jean Lim ,&nbsp;Daniele Castellani ,&nbsp;Bhaskar K. Somani ,&nbsp;Mehmet I. Gökce ,&nbsp;Khi Yung Fong ,&nbsp;Fernando G. Sancha ,&nbsp;Thomas R.W. Herrmann ,&nbsp;Sarvajit Biligere ,&nbsp;Azimdjon N. Tursunkulov ,&nbsp;Marco Dellabella ,&nbsp;Mario Sofer ,&nbsp;Dmitry Enikeev ,&nbsp;Vladislav Petov ,&nbsp;Nariman Gadzhiev ,&nbsp;Dean Elterman ,&nbsp;Abhay Mahajan ,&nbsp;Moises R. Socarras ,&nbsp;Dilmurod S. Yunusov ,&nbsp;Furkat Nasirov ,&nbsp;Jeremy Y.C. Teoh ,&nbsp;Vineet Gauhar","doi":"10.1016/j.prnil.2023.12.001","DOIUrl":"10.1016/j.prnil.2023.12.001","url":null,"abstract":"<div><h3>Background</h3><p>Endoscopic enucleation of the prostate (EEP) has gained acceptance as an equitable alternative to transurethral resection of the prostate for benign prostate hyperplasia (BPH). Our primary aim is to compare peri-operative outcomes of EEP using thulium fiber laser (TFL) against high-power holmium laser (HPHL) in hands of experienced surgeons for large prostates (≥80 ml in volume). Secondary outcomes were assess complications within 1 year of follow up.</p></div><div><h3>Materials and Methods</h3><p>We retrospectively reviewed patients with benign prostatic hyperplasia who underwent EEP with TFL or HPHL in 13 centers (January 2019-January 2023). Patients with prostate volume ≥80 ml were included, while those with concomitant prostate cancer, previous prostate/urethral surgery, and pelvic radiotherapy were excluded.</p></div><div><h3>Results</h3><p>Of 1,929 included patients, HPHL was utilized in 1,459 and TFL in 470. After propensity score matching (PSM) for baseline characteristics, 247 patients from each group were analyzed. Overall operative time (90 [70, 120] vs. 52.5 [39, 93] min, <em>P</em> &lt; 0.001) and enucleation time (90 [70, 105] vs. 38 [25, 70] min, <em>P</em> &lt; 0.001) were longer in the TFL group, with comparable morcellation time (13 [10, 19.5] vs. 13 [10, 16.5] min, <em>P</em> = 0.914). In terms of postoperative outcomes, there were no differences in 30-day complications such as acute urinary retention, urinary tract infection or sepsis. In the PSM cohort, univariable analyses showed that higher age, lower preoperative Qmax, higher preoperative PVRU, and longer operation time were associated with higher odds of postoperative incontinence, while 2-lobe enucleation had lower odds of incontinence compared to 3-lobe enucleation.</p></div><div><h3>Conclusions</h3><p>This real-world study reaffirms that HPHL and TFL in large prostates are equally efficacious in terms of 30-day complications. TFL with the en-bloc technique has a shorter operative time which significantly improves short- and medium-term functional outcomes.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 1","pages":"Pages 40-45"},"PeriodicalIF":3.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888223000727/pdfft?md5=1212268e327c25ef1c3e88bb75013194&pid=1-s2.0-S2287888223000727-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138682502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}